Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Amgen Presents Positive Results In First Phase III For Denosumab At San Antonio

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Firm plans to file BLA in late 2008, early 2009 for post-menopausal osteoporosis and treatment induced osteopenia.

You may also be interested in...



Denosumab Fracture Data Positive In Prostate Cancer Patients

Amgen’s twice-yearly injection still has high bar to pass on fracture risk reduction in postmenopausal women with osteoporosis.

Denosumab Fracture Data Positive In Prostate Cancer Patients

Amgen’s twice-yearly injection still has high bar to pass on fracture risk reduction in postmenopausal women with osteoporosis.

Amgen’s Four-Year Denosumab Data Shows Bone Density Benefit

Wyeth also presents the first Phase III fracture data on its potential competitor Viviant.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

New EU Filings

WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency

Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages

Gene Therapy: Pediatric Development Could Start Sooner Than Sponsors Think – FDA OTP Director

See All
UsernamePublicRestriction

Register

PS065523

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By